Ewa Zarzycka

Gdansk, PM, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.

Journal: Blood advances

Published: March 12, 2025

Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.

Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.

Journal: Therapeutic advances in medical oncology

Published: December 17, 2024

Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.

Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: November 28, 2024

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.

Journal: Haematologica

Published: June 24, 2024

Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.

Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.

Journal: Leukemia & lymphoma

Published: May 22, 2024

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.

Journal: Frontiers in oncology

Published: March 05, 2024

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.

Journal: Frontiers in oncology

Published: May 24, 2023

Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature.

Isolated Progression of Multiple Myeloma into the Extramedullary Plasmacytoma of Dura Mater: A Case Report and Review of the Literature.

Journal: Biomedicines

Published: January 06, 2023

Cold-induced urticaria-like lesions related to NLRP-12 mutation.

Cold-induced urticaria-like lesions related to NLRP-12 mutation.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 21, 2022

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: April 20, 2022

Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors.

Ageing-resembling phenotype of long-term allogeneic hematopoietic cells recipients compared to their donors.

Journal: Immunity & ageing : I & A

Published: April 12, 2022

Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation.

Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation.

Journal: Kardiologia polska

Published: March 27, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026